Compare Aventis Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ABBOTT INDIA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ABBOTT INDIA SANOFI INDIA/
ABBOTT INDIA
 
P/E (TTM) x 43.1 55.6 77.5% View Chart
P/BV x 7.9 16.4 48.1% View Chart
Dividend Yield % 1.1 0.4 263.4%  

Financials

 SANOFI INDIA   ABBOTT INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ABBOTT INDIA
Mar-19
SANOFI INDIA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6,8408,834 77.4%   
Low Rs4,6305,458 84.8%   
Sales per share (Unadj.) Rs1,203.11,731.1 69.5%  
Earnings per share (Unadj.) Rs165.3211.9 78.0%  
Cash flow per share (Unadj.) Rs209.9219.9 95.4%  
Dividends per share (Unadj.) Rs84.0065.00 129.2%  
Dividend yield (eoy) %1.50.9 161.0%  
Book value per share (Unadj.) Rs963.6945.2 101.9%  
Shares outstanding (eoy) m23.0321.25 108.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.1 115.5%   
Avg P/E ratio x34.733.7 102.9%  
P/CF ratio (eoy) x27.332.5 84.1%  
Price / Book Value ratio x6.07.6 78.7%  
Dividend payout %50.830.7 165.7%   
Avg Mkt Cap Rs m132,078151,848 87.0%   
No. of employees `0003.33.5 94.7%   
Total wages/salary Rs m4,0684,356 93.4%   
Avg. sales/employee Rs Th8,393.810,555.5 79.5%   
Avg. wages/employee Rs Th1,232.41,249.9 98.6%   
Avg. net profit/employee Rs Th1,153.01,292.2 89.2%   
INCOME DATA
Net Sales Rs m27,70836,786 75.3%  
Other income Rs m8971,133 79.2%   
Total revenues Rs m28,60537,919 75.4%   
Gross profit Rs m6,2356,047 103.1%  
Depreciation Rs m1,027169 607.0%   
Interest Rs m723 31.1%   
Profit before tax Rs m6,0986,989 87.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2922,485 92.2%   
Profit after tax Rs m3,8064,503 84.5%  
Gross profit margin %22.516.4 136.9%  
Effective tax rate %37.635.6 105.7%   
Net profit margin %13.712.2 112.2%  
BALANCE SHEET DATA
Current assets Rs m15,92227,610 57.7%   
Current liabilities Rs m6,2358,569 72.8%   
Net working cap to sales %35.051.8 67.5%  
Current ratio x2.63.2 79.3%  
Inventory Days Days6460 105.7%  
Debtors Days Days2127 76.2%  
Net fixed assets Rs m7,5391,057 713.3%   
Share capital Rs m230213 108.2%   
"Free" reserves Rs m21,96219,873 110.5%   
Net worth Rs m22,19220,086 110.5%   
Long term debt Rs m00-   
Total assets Rs m29,83929,409 101.5%  
Interest coverage x872.1311.6 279.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 74.2%   
Return on assets %12.815.4 83.0%  
Return on equity %17.222.4 76.5%  
Return on capital %27.534.9 78.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,587369 2,056.3%   
Fx outflow Rs m7,1454,918 145.3%   
Net fx Rs m442-4,549 -9.7%   
CASH FLOW
From Operations Rs m3,7394,991 74.9%  
From Investments Rs m-731-2,570 28.4%  
From Financial Activity Rs m-1,972-1,428 138.1%  
Net Cashflow Rs m1,036993 104.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 7.9 182.3%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   15,184 18,270 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   DR. REDDYS LAB  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Energy and IT Stocks Witness Buying(Closing)

After opening the day on a strong note, Indian share markets erased most of the gains and turned highly volatile in the afternoon session.

Related Views on News

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Jul 13, 2020 | Updated on Jul 13, 2020

GRANULES INDIA share price has hit an all time high at Rs 245 (up 4.0%). The BSE HEALTHCARE Index is up by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (up 4.0%) and SANOFI INDIA (up 0.2%). The top losers include DISHMAN CARBOGEN AMCIS LTD (down 0.1%) and ABBOTT INDIA (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jul 13, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - AJANTA PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS